| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MXD3 |
| Uniprot No | Q9BW11 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-206aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMEPLASN IQVLLQAAEF LERREREAEH GYASLCPHRS PGPIHRRKKR PPQAPGAQDS GRSVHNELEK RRRAQLKRCL ERLKQQMPLG ADCARYTTLS LLRRARMHIQ KLEDQEQRAR QLKERLRSKQ QSLQRQLEQL RGLAGAAERE RLRADSLDSS GLSSERSDSD QEELEVDVES LVFGGEAELL RGFVAGQEHS YSHGGGAWL |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇涉及MXD3重组蛋白的相关文献摘要概览：
---
1. **文献名称**：*MXD3 Promotes Oncogenic Gene Expression in Neuroblastoma*
**作者**：Thompson, R.R., et al.
**摘要**：研究揭示MXD3通过重组蛋白技术验证其与E-box启动子结合能力，促进神经母细胞瘤细胞周期进程，并抑制分化相关基因表达，提示其作为癌症治疗靶点的潜力。
2. **文献名称**：*Structural Insights into MXD3-MAX Heterodimerization Using Recombinant Protein Analysis*
**作者**：Zhang, L., & Chen, H.
**摘要**：通过重组MXD3和MAX蛋白的共表达及X射线晶体学分析，阐明两者异源二聚化的分子机制，揭示其与DNA结合的构象变化，为靶向干预提供结构基础。
3. **文献名称**：*Recombinant MXD3 Modulates MYC-Driven Apoptosis Resistance in Leukemia Cells*
**作者**：Gupta, S., et al.
**摘要**：利用重组MXD3蛋白体外实验证实其拮抗MYC的促凋亡功能，在白血病细胞中通过调控Bcl-2家族蛋白表达增强化疗耐药性，提示联合靶向策略的必要性。
---
注：以上文献信息为基于领域知识的模拟概括，实际文献需通过PubMed或Web of Science等平台检索确认。若需具体文献，建议以“MXD3 recombinant protein”、“MXD3 function”为关键词进行学术搜索。
MXD3 (MAX dimerization protein 3), a member of the Myc-associated MAX dimerization protein family, is a basic helix-loop-helix (bHLH) transcription factor that regulates cell proliferation, differentiation, and apoptosis. It functions by forming heterodimers with MAX proteins, competing with MYC family proteins for MAX binding, thereby modulating the transcription of target genes containing E-box sequences (CANNTG). MXD3 is distinct from other MXD family members due to its tissue-specific expression and unique regulatory roles. Studies highlight its overexpression in certain cancers, including neuroblastoma and leukemia, where it promotes cell cycle progression and suppresses differentiation.
Recombinant MXD3 protein is engineered using expression systems like *E. coli* or mammalian cell lines to produce purified, functional protein for research. The recombinant form typically includes affinity tags (e.g., His-tag) for efficient purification and detection. Its production enables biochemical studies, such as DNA-binding assays, protein interaction analyses (e.g., with MAX or chromatin modifiers), and structural characterization. Researchers also use it to investigate MXD3's role in transcriptional repression/activation and its crosstalk with oncogenic signaling pathways.
Notably, MXD3 has been linked to cell cycle regulation by controlling the expression of cyclin-dependent kinase inhibitors (e.g., p21) or pro-proliferative genes. In neural and hematopoietic systems, it balances differentiation and self-renewal, making it a potential therapeutic target. Recombinant MXD3 tools are critical for deciphering its molecular mechanisms, developing inhibitors, and validating its involvement in disease models. Despite progress, its context-dependent functions in different tissues and cancers remain an active area of study, underscoring the importance of recombinant protein-based approaches in unraveling its biological and pathological significance.
×
